

# Jean Klastersky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6195697/publications.pdf>

Version: 2024-02-01

37  
papers

2,528  
citations

430754

18  
h-index

377752

34  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1936  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 3038-3051.	0.8	991
2	Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy. <i>New England Journal of Medicine</i> , 1999, 341, 312-318.	13.9	360
3	Management of Fever in Neutropenic Patients with Different Risks of Complications. <i>Clinical Infectious Diseases</i> , 2004, 39, S32-S37.	2.9	204
4	Outpatient Oral Antibiotics for Febrile Neutropenic Cancer Patients Using a Score Predictive for Complications. <i>Journal of Clinical Oncology</i> , 2006, 24, 4129-4134.	0.8	180
5	The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10Âyears of use for identifying low-risk febrile neutropenic cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 1487-1495.	1.0	99
6	Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 163-179.	2.0	74
7	Antifungal Therapy in Patients with Fever and Neutropenia â€” More Rational and Less Empirical?. <i>New England Journal of Medicine</i> , 2004, 351, 1445-1447.	13.9	67
8	Adverse effects of the humanized antibodies used as cancer therapeutics. <i>Current Opinion in Oncology</i> , 2006, 18, 316-320.	1.1	67
9	Methodology for Clinical Trials Involving Patients with Cancer Who Have Febrile Neutropenia: Updated Guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with Emphasis on Outpatient Studies. <i>Clinical Infectious Diseases</i> , 2002, 35, 1463-1468.	2.9	57
10	Febrile neutropenia: A critical review of the initial management. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 185-194.	2.0	48
11	Empirical antifungal therapy. <i>International Journal of Antimicrobial Agents</i> , 2004, 23, 105-112.	1.1	47
12	Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?. <i>Supportive Care in Cancer</i> , 2011, 19, 1001-1008.	1.0	36
13	Risk-adapted strategy for the management of febrile neutropenia in cancer patients. <i>Supportive Care in Cancer</i> , 2007, 15, 477-482.	1.0	30
14	111Indium-oxine-labeled leukocytes in the diagnosis of localized infection in patients with neoplastic disease. <i>Cancer</i> , 1984, 54, 817-824.	2.0	27
15	Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). <i>Critical Reviews in Oncology/Hematology</i> , 2011, 81, 49-57.	2.0	24
16	Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 3015-3022.	1.0	20
17	Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 17-23.	2.0	19
18	Why empirical therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, i14-i15.	1.3	18

#	ARTICLE	IF	CITATIONS
19	Ambulatory Outpatient Management of patients with low risk febrile neutropaenia. <i>Acute Medicine</i> , 2015, 14, 178-81.	0.1	18
20	Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?. <i>Current Opinion in Oncology</i> , 2009, 21, 297-302.	1.1	16
21	The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013. <i>Supportive Care in Cancer</i> , 2016, 24, 2819-26.	1.0	16
22	Supportive/palliative care in cancer patients: quo vadis?. <i>Supportive Care in Cancer</i> , 2016, 24, 1883-1888.	1.0	16
23	Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study. <i>BMC Cancer</i> , 2018, 18, 917.	1.1	15
24	Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection. <i>Supportive Care in Cancer</i> , 2007, 15, 137-141.	1.0	12
25	From best supportive care to early palliative care. <i>Current Opinion in Oncology</i> , 2011, 23, 311-312.	1.1	12
26	Empirical treatment of sepsis in neutropenic patients. <i>British Journal of Hospital Medicine</i> , 2001, 62, 101-103.	0.3	10
27	Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 268-278.	2.0	10
28	The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia. <i>Supportive Care in Cancer</i> , 2013, 21, 1793-1795.	1.0	7
29	Erdheim-Chester Disease: A Case Report. <i>American Journal of Case Reports</i> , 2015, 16, 361-366.	0.3	6
30	Prevention of neutropenia-related events in elderly patients with hematological cancer. <i>Aging Health</i> , 2011, 7, 829-842.	0.3	4
31	Use of low-level laser therapy (LLLT) or photobiomodulation (PBM) for the management of the hand-foot syndrome (HSF) or palmo-plantar erythrodysesthesia (PPED) associated with cancer therapy. <i>Supportive Care in Cancer</i> , 2020, 28, 3287-3290.	1.0	4
32	Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer. <i>Current Opinion in Oncology</i> , 2018, 30, 98-104.	1.1	3
33	Supportive care: new trends and new needs. <i>Current Opinion in Oncology</i> , 2010, 22, 301.	1.1	2
34	Old age: An extra risk for febrile neutropenia?. <i>Journal of Geriatric Oncology</i> , 2017, 8, 84-85.	0.5	1
35	<i>Infections and Cancer</i> , 2018, , 337-348.		0
36	Supportive care for cancer patients: a survey of available settings and current practices in Belgium. <i>Supportive Care in Cancer</i> , 2021, 29, 5507-5512.	1.0	0

#	ARTICLE	IF	CITATIONS
37	Management of the Low-Risk Patients. , 2014, , 35-42.		0